Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MT-202
- Development stage
- Preclinical
- Lead developer
- Curacle
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
MT-202 is a small molecule dual agonist targeting G protein-coupled receptor 119 (GPR119) and free fatty acid receptor 1 (GPR40/FFAR1), currently in preclinical development by Curacle for the treatment of non-alcoholic steatohepatitis (NASH), also known as metabolic dysfunction-associated steatohepatitis (MASH). As part of Curacle's metabolic therapy (MT) pipeline, MT-202 is designed to address the complex metabolic and inflammatory components of NASH. By stimulating both GPR119 and GPR40, the drug aims to improve glucose metabolism, reduce hepatic fat accumulation, and mitigate liver inflammation and fibrosis. The dual-action mechanism is intended to provide superior efficacy over single-target agents in managing the multifaceted pathophysiology of metabolic liver diseases.
02
Targets
TEK (Tie2)
Beyond the preview
Go deeper on MT-202.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MT-202.